eMedicine Specialties > Infectious Diseases > Sexually Transmitted Diseases

Papillomavirus: Follow-up

Author: John D Shanley, MD, MPH, Professor Emeritus, University of Connecticut; Professor of Preventive Medicine, Stony Brook Medical Center
Contributor Information and Disclosures

Updated: Aug 15, 2007

Follow-up

Further Outpatient Care

  • Because papillomaviruses reside in the basal layer of the epidermis in a latent state, recurrences are common and retreatment is often necessary. For genital neoplasia, careful follow-up is mandatory.
  • Treatment of cervical intraepithelial neoplasia, grade 1 (CIN 1) may be monitored safely with serial cytology and colposcopy in reliable patients. Perform PAP tests every 6 months and colposcopy every 2 years. Treatment options include carbon dioxide laser ablation or excision, cryotherapy for lesions of 2 quadrants or less, cone biopsy, or loop excision.
  • For anal and rectal lesions in the context of HIV, frequent follow-up is essential.

Deterrence/Prevention

  • In 2006, the FDA approved the papillomavirus vaccine Gardasil (Merck and Co.). This vaccine is a quadrivalent vaccine that contains the major capsid protein, L1, for HPV types 6, 11, 16, and 18. Types 6 and 11 are associated with genital warts, while types 16 and 18 are associated with more than 70% of cervical malignancy cases. The vaccine is produced via recombinant technology to synthesize viruslike particles (VLPs) that are formed when L1 is expressed in vitro. VLPs are morphologically identical to the HPV but lack the viral genome. The vaccine is administered with a proprietary adjuvant of amorphous aluminum hydroxyphosphate sulfate. The vaccine is administered intramuscularly at 0, 2, and 6 months. The most common adverse effects include local irritation (swelling, pain, redness, itching) and fever. It is not approved for use in pregnant women.
  • Clinical trials have demonstrated a high degree of efficacy in preventing cytological changes due to HPV or clinical disease. The vaccine induces antibody responses that are 80-100 times that of natural infection.
  • The Advisory Committee on Immunization Practices gave provisional recommendations for immunization of females beginning at age 11 or 12 uears. Catch-up vaccination was recommended for females aged 13-26 years.

Prognosis

Papillomavirus infection primarily involves the basal epithelial cells. As a result, recurrences are common. Spontaneous regressions are also common.

Patient Education

For excellent patient education resources, visit eMedicine's Warts Center and Cancer and Tumors Center. Also, see eMedicine's patient education articles Warts, Genital Warts, Plantar Warts, Cervical Cancer, Birth Control Overview, and Birth Control FAQs.

Miscellaneous

Medicolegal Pitfalls

  • Few legal issues are associated with papillomavirus infection. Legal issues largely are the result of either a failure to diagnose or, more commonly, the adverse effects of treatment.
    • The treatment of most papillomavirus infections involves agents that directly ablate the lesions (eg, surgical excision, chemical ablation, cryotherapy). Inappropriate use of these agents may cause extensive and unnecessary tissue injury and loss.
    • Podophyllin treatment is a special case because this agent not only causes tissue injury but also can be absorbed systemically and cause neurological toxicity. Deaths have occurred with the use of podophyllin on exuberant perianal warts; the surface area of the lesions increases the absorption of drug.
 


More on Papillomavirus

Overview: Papillomavirus
Differential Diagnoses & Workup: Papillomavirus
Treatment & Medication: Papillomavirus
Follow-up: Papillomavirus
Multimedia: Papillomavirus
References
[ CLOSE WINDOW ]

References

  1. Ault KA. Human papillomavirus infections: diagnosis, treatment, and hope for a vaccine. Obstet Gynecol Clin North Am. Dec 2003;30(4):809-17. [Medline].

  2. Beutner KR, Ferenczy A. Therapeutic approaches to genital warts. Am J Med. May 5 1997;102(5A):28-37. [Medline].

  3. Carr J, Gyorfi T. Human papillomavirus. Epidemiology, transmission, and pathogenesis. Clin Lab Med. Jun 2000;20(2):235-55. [Medline].

  4. Fazel N, Wilczynski S, Lowe L, Su LD. Clinical, histopathologic, and molecular aspects of cutaneous human papillomavirus infections. Dermatol Clin. Jul 1999;17(3):521-36, viii. [Medline].

  5. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. May 5 1997;102(5A):3-8. [Medline].

  6. Sedlacek TV. Advances in the diagnosis and treatment of human papillomavirus infections. Clin Obstet Gynecol. Jun 1999;42(2):206-20. [Medline].

  7. Tjalma WA, Arbyn M, Paavonen J, van Waes TR, Bogers JJ. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer. Int J Gynecol Cancer. Sep-Oct 2004;14(5):751-61. [Medline].

  8. Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis. Oct 15 2002;35(Suppl 2):S210-24. [Medline].

  9. Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs. 2006;66(9):1263-71; discussion 1272-3. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

human papillomavirus, HPV, common warts, verruca vulgaris, palmo-plantar warts, flat warts, verruca plana, oral warts, focal epithelia hyperplasia, epidermodysplasia verruciformis, EDV, genital warts, condyloma acuminata, Bowen papulosis, Bowen disease, papillomas of the mucosal surfaces, intraepithelial neoplasias, papovavirus, sexually transmitted disease, STD, laryngeal papillomas, mosaic wart, butcher wart, extragenital Bowen disease, macular plaque, flat condylomata, cervical intraepithelial neoplasia, Buschke-Löwenstein tumor, vulvar intraepithelial neoplasia, cervical cancer, penile intraepithelial neoplasia, anal intraepithelial neoplasia, verrucae vulgaris, verrucae plana, Heck disease, flat condylomata, squamous intraepithelial neoplasia, giant condyloma, verrucous carcinoma, Bowenoid papulosis

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

John D Shanley, MD, MPH, Professor Emeritus, University of Connecticut; Professor of Preventive Medicine, Stony Brook Medical Center
John D Shanley, MD, MPH is a member of the following medical societies: American Association for the Advancement of Science, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Medical Editor

Jeffrey D Band, MD, Clinical Professor of Medicine, Wayne State University School of Medicine; Director, Division of Infectious Diseases and International Medicine, William Beaumont Hospital Corporation
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Charles V Sanders, MD, Edgar Hull Professor and Chairman, Department of Internal Medicine, Professor of Microbiology, Immunology and Parasitology, Louisiana State University School of Medicine at New Orleans; Medical Director, Medicine Hospital Center, Charity Hospital and Medical Center of Louisiana at New Orleans; Consulting Staff, Ochsner Medical Center
Charles V Sanders, MD is a member of the following medical societies: Alliance for the Prudent Use of Antibiotics, Alpha Omega Alpha, American Association for the Advancement of Science, American Association of University Professors, American Clinical and Climatological Association, American College of Physician Executives, American College of Physicians, American Federation for Medical Research, American Foundation for AIDS Research, American Geriatrics Society, American Lung Association, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Association for Professionals in Infection Control and Epidemiology, Association of American Medical Colleges, Association of American Physicians, Association of Professors of Medicine, Infectious Disease Society for Obstetrics and Gynecology, Infectious Diseases Society of America, Louisiana State Medical Society, Orleans Parish Medical Society, Royal Society of Medicine, Sigma Xi, Society of General Internal Medicine, Southeastern Clinical Club, Southern Medical Association, Southern Society for Clinical Investigation, and Southwestern Association of Clinical Microbiology
Disclosure: Nothing to disclose.

CME Editor

Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital
Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital
Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.